Flags with the Novo Nordisk logodesign flutter exterior their Danish business’s workplaces in Copenhagen, Denmark, September 26,2023 REUTERS/Tom Little/File Photo Acquire Licensing Rights
COPENHAGEN, Oct 16 (Reuters) – Novo Nordisk (NOVOb.CO) has concurred to buy ocedurenone, a drug for unchecked highbloodpressure with capacity application in cardiovascular and kidney illness, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker stated on Monday.
“This offer is carefully linedup with our tactical focus on broadening from our core in diabetes into other severe persistent illness, consistingof through unique drug methods,” Novo stated in a declaration.
The acquisition is anticipated to close before the end of this year, Novo stated, including that the offer will not effect its operating revenue outlook for 2023.
Ocedurenone is an orally administered drug that is presently takenalookat in the stage 3 trial CLARION-CKD in clients with unchecked highbloodpressure and sophisticated persistent